NCT07159321

Brief Summary

This study addresses a critical gap in the care of older women with breast cancer, a population often underrepresented in clinical research despite their increased vulnerability to treatment-related complications. By examining the relationship between frailty and health-related quality of life (QOL), the study aims to provide evidence-based insights into how geriatric assessments can guide personalized treatment decisions, ensuring that therapeutic benefits outweigh risks. Given that older adults prioritize QOL over survival gains, understanding the impact of frailty on their well-being can help clinicians optimize care plans, reduce adverse outcomes, and improve overall patient-centered outcomes. The findings may also inform the integration of routine geriatric assessments in oncology practice, ultimately enhancing the management of older cancer patients in resource-limited settings like Egypt.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
5mo left

Started Sep 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress63%
Sep 2025Sep 2026

First Submitted

Initial submission to the registry

July 14, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 8, 2025

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2026

Last Updated

September 8, 2025

Status Verified

September 1, 2025

Enrollment Period

12 months

First QC Date

July 14, 2025

Last Update Submit

September 5, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in the Quality of life measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 and 23.

    Health-related quality of life will be assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) together with the Breast Cancer-Specific Module. Both instruments generate scores ranging from 0 to 100. For functional domains and global health status, higher scores indicate better quality of life, whereas for symptom domains, higher scores indicate more severe symptoms and worse outcomes at baseline and 6 months.

    6 months

Secondary Outcomes (1)

  • change in Frailty status as assessed by clinical frailty scale

    6 months

Study Arms (1)

Females aged 60 years and older, who are newly diagnosed with pathologically proven breast inva

Other: Comprehensive geriatric assessmentOther: European Organization for Research and Treatment-Quality of life questionnaireOther: Clinical Frailty Scale

Interventions

Functional status will be evaluated using Activities of Daily Living (ADL) (assessing bathing, dressing, toileting, transferring, eating, and continence; Katz, 1970) and Instrumental ADL (IADL) (assessing shopping, cooking, medication management, phone use, housework, laundry, transportation, and finances; Lawton \& Brody, 1969). Nutritional status will be measured via the Mini-Nutritional Assessment-Short Form (MNA-SF) (Arabic version; Abd-Al-Atty et al., 2012), a 6-item tool (appetite, weight loss, mobility, illness, neuropsychological issues, BMI) scored 0-14, classifying patients as well-nourished (≥12), at risk (8-11), or malnourished (0-7; Rubenstein et al., 2001). Cognition will be assessed using the Saint Louis University Mental Status (SLUMS) exam (Arabic version; Abdelrahamn et al., 2014), a 30-point test evaluating calculation, orientation, memory, fluency, and visuospatial function, with dementia thresholds at \<20 (\<12 years education) or \<21 (≥12 years; Tariq et al., 2006).

Females aged 60 years and older, who are newly diagnosed with pathologically proven breast inva

Quality of life assessment by European Organization for Research and Treatment-Quality of life questionnaire and breast cancer-specific module (EORTC QLQ-C30)and QLQ-BR23) EORTC QLQ-C30 is a validated tool designed to measure cancer patients' physical, psychological and social functions. It consists of 30 items measuring Global Health status (2 items), Functional scales (15 items) and Symptoms scales/items (13 items). Items were measured using a 4-point Likert Scale ranging from Not at all (1) to Very much (4). EORTC-BR23 consists of 23 items which measure two main scales "Functional Scale (8 items) and "Symptoms scales (15 items). Items measured using 4-point Likert Scale ranging from Not at all (1) to Very much (4).

Females aged 60 years and older, who are newly diagnosed with pathologically proven breast inva

Frailty will be assessed using the Clinical Frailty Scale (CFS), a validated and widely used tool developed by (Rockwood et al., 2005). The CFS is a 9-point ordinal scale that categorizes older adults based on their level of physical fitness, functional independence, and comorbidities, ranging from 1 indicate very fit to 9 indicate terminally ill. Participants were evaluated by trained clinicians based on their clinical judgment, incorporating information from patient interviews. The scale provides a practical and reliable measure of frailty in geriatric populations and has demonstrated strong predictive validity for adverse health outcomes including hospitalization, institutionalization, and mortality.

Females aged 60 years and older, who are newly diagnosed with pathologically proven breast inva

Eligibility Criteria

Age60 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

older females; 60 years old or older, diagnosed with breast cancer before receiving chemotherapy will be recruited from the clinical oncology department, Ain Shams university hospitals.

You may qualify if:

  • Females aged 60 years and older
  • Newly diagnosed with pathologically proven breast invasive ductal or lobular carcinoma

You may not qualify if:

  • History of cognitive impairment or psychiatric disorders
  • Delirium during assessment using the Confusion Assessment Method (CAM test)
  • Initiation of chemotherapy before the baseline assessment
  • Severe hearing or visual impairment preventing completion of assessment
  • Other malignancies (second primary)
  • Other breast malignancies (e.g., sarcoma)
  • End-organ failure (e.g., renal failure, liver cell failure)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Frailty

Interventions

Geriatric Assessment

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth StatusDemographyPopulation CharacteristicsHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationEpidemiologic MeasurementsPublic HealthEnvironment and Public Health

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant lecturer of Geriatric medicine

Study Record Dates

First Submitted

July 14, 2025

First Posted

September 8, 2025

Study Start

September 1, 2025

Primary Completion (Estimated)

August 30, 2026

Study Completion (Estimated)

September 30, 2026

Last Updated

September 8, 2025

Record last verified: 2025-09